Clinical Trial Detail

NCT ID NCT01379534
Title A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

endometrial cancer

Therapies

Dovitinib

Age Groups: senior adult

No variant requirements are available.